Our Science
Dr. Nelson Handal, M.D., DFAPA founded clinicom to detecting, diagnosing and improving outcomes for mental health conditions.
Clinicom’s Team have been an integral part of some of the most sensitive and pivotal independent CNS Clinical Trials supporting pharma companies drug development for the last 20 years. Pharma has trusted our team with their most sensitive IP and the responsibility of accurately measuring mental health for FDA trials for two decades. In 2022, Clinicom CEO Ignacio Handal was awarded the Christine Pierre Lifetime Achievement Award in Clinical Research, This global award recognized his ongoing contribution to FDA Clinical Trials that has positively impacted 200 million lives through a myriad of drug and device approvals. This award is the highest honor in Clinical Trial Research globally.
As reported by Globaldata.com, our Founders, Chairman, CEO, CMO, and Director of Research have each independently conducted more pharma clinical trial research than 99.2% of all Global PIs, SubIs, and other Researchers combined, across all therapeutic areas. Part of the reason pharma has repeatedly selected our independent CNS research site is because of the Clinicom platform we developed through our CRO, and the sophisticated screening tools we developed to screen and measure mental health, earning us a strong reputation within FDA clinical trials, Pharma, life sciences, and the CRO space.
Clinicom has been through X evidence-based Y clinical validations, Z peer-reviewed publications, and rigorous testing, ensuring we adhered to the highest clinical and scientific standards.
Validation, reliability, and specificity of CliniCom™ Psychiatric Assessment Software
Handal, N., LePage, J., Dayley, P., Baldwin, B., Roeser, A., Kay, J., Theobald, H. A., Nellamattathil, M., Drotar, S., Weir, C., Tindell, N., & Tice, K. (2018). . Psychiatry research, 265, 334–340.